A multicenter prospective study on the diagnostic performance of a new liquid rapid urease test for the diagnosis of Helicobacter pylori infection
Authors:
- Werner DolakWDWerner Dolak
- Ceren BilgilierCBCeren Bilgilier
- Alexander StadlmannASAlexander Stadlmann
- Judith LeinerJLJudith Leiner
- Andreas PüspökAPAndreas Püspök
- Wolfgang PlieschneggerWPWolfgang Plieschnegger
- Franz SiebertFSFranz Siebert
- Friedrich WewalkaFWFriedrich Wewalka
- Rainer SchöflRSRainer Schöfl
- Ursula Huber-SchönauerUHUrsula Huber-Schönauer
- Christian DatzCDChristian Datz
- Susanne Biowski-FrotzSBSusanne Biowski-Frotz
Open Access
- 22 December 2017
- journal article
- research article
- Published by Springer Nature in Gut Pathogens
- Vol. 9 (1) , 1-5
Abstract
Background: Helicobacter pylori (H. pylori) causes a diversity of gastric diseases. Rapid urease tests (RUT) are well established for the point-of-care, invasive diagnosis of H. pylori infection. The study aimed to evaluate the diagnostic performance of a new liquid RUT, the preOx-HUT, within a prospective cohort of treatment-naïve patients. Methods: The multicenter prospective clinical trial was conducted at nine Austrian centers for gastrointestinal endoscopy. Patients referred for a diagnostic upper gastrointestinal endoscopy underwent gastric biopsy sampling for routine histological evaluation, and in parallel, the preOx-HUT. Histology served as reference standard to evaluate the diagnostic performance of the preOx-HUT. Results: From January 2015 to January 2016, a total of 183 consecutive patients (54 males and 129 females, median age 50 years) were included. Endoscopy revealed pathological findings in 149/183 cases (81%), which were mostly gastritis (59%) and gastro-esophageal reflux disease (27%). H. pylori infection was detected by histology in 41/183 (22%) cases. In relation to histology, the preOx-HUT had a sensitivity of 85%, a specificity of 94%, a positive predictive value of 80% and a negative predictive value of 96%. Performance of preOx-HUT was not affected significantly by concomitant PPI-use as present in 15% of cases (P = 0.73). Conclusions: This was the first study evaluating the preOx-HUT in a prospective, multicenter clinical setting. We found a high diagnostic accuracy for the point-of-care, invasive diagnostic test of H. pylori infection. Hence, this test may be a valuable diagnostic adjunct to the clinical presentation of patients with suspected H. pylori infection. Trial registration number EK 1548/2014, Name of registry: Register der Ethikkommission der Medizinischen Universität Wien, URL of registry: https://ekmeduniwien.at/core/catalog/2012/, Date of registration: 24.09.2014, Date of enrolment of the first participant to the trial: 15.01.2015Keywords
Funding Information
- Austrian Science Fund (P28102-B30)
This publication has 23 references indexed in Scilit:
- A combined antral and corpus rapid urease testing protocol can increase diagnostic accuracy despite a low prevalence of Helicobacter pylori infection in patients undergoing routine gastroscopyUnited European Gastroenterology Journal, 2015
- Helicobacter Pylori Infection: Diagnostic Strategies in Primary Diagnosis and After TherapyDigestive Diseases and Sciences, 2015
- Diagnosis of Helicobacter pylori using the rapid urease test2015
- Changing prevalence patterns in endoscopic and histological diagnosis of gastritis? Data from a cross-sectional Central European multicentre studyDigestive and Liver Disease, 2014
- Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus ReportGut, 2012
- A comparison amongst three rapid urease tests to diagnose Helicobacter pylori infection in 375 consecutive dyspepticInternal and Emergency Medicine, 2010
- Accuracy of Diagnostic Tests forHelicobacter pylori:A ReappraisalClinical Infectious Diseases, 2009
- Near-patient assays for diagnosis of influenza virus infection in adult patientsClinical Microbiology and Infection, 2009
- Helicobacter pyloriInfectionNew England Journal of Medicine, 2002
- Is routine histological evaluation an accurate test for Helicobacter pylori infection?Alimentary Pharmacology & Therapeutics, 1999